Market's view on PureTech
Published on April 2024
- A stock watcher points out the importance of focusing on fundamentals despite daily market fluctuations.
- Frustration is shared by another due to hesitation in selling holdings at a high, fearing further price increase, especially with an upcoming tender in early May.
- Speculation about market manipulation before a tender announcement, suggesting potential financial gains.
- A comparison is made between poor companies that rise on basic results and good companies that don’t see much movement even with great results, highlighting the unpredictability of the stock market.
- Discussion about companies being taken out at prices much higher than their current trading levels in recent years.
- Frustration is expressed about the company’s inability to demonstrate its true value to the market.
- A claim is presented about the company’s impressive track record in the biopharma industry, with a high success rate in clinical trials and a robust pipeline of new medicines.
- Positive results are discussed with a mention of untapped significant value that is not recognized by the market, suggesting future strategies to unlock this value for shareholders.
- Curiosity about why shares are undervalued and the lack of significant movements in share prices, even with positive updates.
- Concerns are voiced about the management changes upsetting long-term investors and a perceived low tender offer price.
- The importance of tax implications for US-based companies on UK investors is discussed, specifically the need for a Section 302 certification form to avoid withholding tax on tender offers.